Restoring balance.
Renewing life.

Akero is pioneering novel therapies to transform the lives of people living with serious metabolic diseases.
Learn More
Learn More

Advancing Efruxifermin (EFX) for NASH

Our flagship EFX program is designed to be a differentiated, potentially best-in-class treatment for non-alcoholic steatohepatitis (NASH)

Learn more

Ongoing Clinical Studies

We have multiple ongoing clinical trials to evaluate our investigational drug, EFX, as a treatment for NASH.

Learn more

Recent Press Releases from Akero

03/17/2023

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

01/10/2023

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

01/04/2023

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

View All

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions